67.70 USD
↘ 0.86 (1.25%)AT CLOSE (11:59 AM EDT)
CG Oncology, Inc. Common stock
CGONNASDAQ • USD
68.37
↗ 0.67 (0.99%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
68.37
↗ 0.67 (0.99%)
Market: CLOSED
Open?$68.47
High?$68.90
Low?$67.51
Prev. Close?$68.56
Volume?1.2M
Avg. Volume?1.5M
VWAP?$68.08
Rel. Volume?0.81x
Bid / Ask
Bid?$66.75 × 100
Ask?$70.00 × 100
Spread?$3.25
Midpoint?$68.38
Valuation & Ratios
Market Cap?5.7B
Shares Out?84.4M
Float?53.8M
Float %?66.7%
P/E Ratio?N/A
P/B Ratio?7.60
EPS?-$1.91
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?24.63Strong
Quick Ratio?24.58Strong
Cash Ratio?1.05Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?7.60FAIR▾
P/S?1,414.92HIGH▾
P/FCF?N/A▾
EV/EBITDA?-30.0CHEAP▾
EV/Sales?1,407.62HIGH▾
Returns & Efficiency
ROE?-21.4%WEAK▾
ROA?-20.3%WEAK▾
Cash Flow & Enterprise
FCF?$-132480000
Enterprise Value?$5.7B
Related Companies
Loading...
News
Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Employees
142
Market Cap
5.7B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2024-01-25
Address
400 SPECTRUM CENTER DRIVE
IRVINE, CA 92618
Phone: (949) 419-6203
IRVINE, CA 92618
Phone: (949) 419-6203